Paper39166327
Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.
Yu M and 12 others. Circulation, 2024. Cited by 102 papers, by iCite.
Cite this record
ConductScience Library. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial. Papers, record 39166327. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39166327
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colchicine | Major topic |
| Acute Coronary Syndrome | Major topic |
| Tomography, Optical Coherence | Major topic |
| Plaque, Atherosclerotic | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| Male | |
| Double-Blind Method | |
| Aged | |
| Prospective Studies | |
| Adult | |
| Treatment Outcome | |
| Coronary Artery Disease |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04848857 | Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT) | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 39325503 | Colchicine and Atherothrombosis: Another Piece of the Puzzle. | https://conductscience.org/library/papers/39325503 |
Source PubMed
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42888064 | Taming inflammation in coronary artery disease: lessons learned, translational breakthroughs, and future directions. | Sci Bull (Beijing) | 2026 | https://conductscience.org/library/papers/42888064 | PubMed |
| 42676490 | Beyond lipids: a precision prevention blueprint for China's residual risk. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42676490 | PubMed |
| 42440890 | Advances in the Diagnosis and Management of Acute Coronary Syndrome: A Clinical Review. | Cureus | 2026 | https://conductscience.org/library/papers/42440890 | PubMed |
| 42438017 | Atherosclerotic Cardiovascular Disease and Cancer. | Immunol Rev | 2026 | https://conductscience.org/library/papers/42438017 | PubMed |
| 42437951 | Anti-inflammatory agents in atherosclerosis-and a need for reform: Extraordinary claims require extraordinary evidence. | J Intern Med | 2026 | https://conductscience.org/library/papers/42437951 | PubMed |
| 42346504 | Colchicine in Coronary Artery Disease-Too Much of a Good Thing? | J Cardiovasc Dev Dis | 2026 | https://conductscience.org/library/papers/42346504 | PubMed |
| 42279002 | Anti-Inflammatory Therapies in Acute Coronary Syndromes-A Review of Immunological, Genetic, and Clinical Challenges for Precision Medicine. | J Clin Med | 2026 | https://conductscience.org/library/papers/42279002 | PubMed |
| 42196392 | Colchicine in Cardiovascular Disease: Evidence Structure, Clinical Efficacy, Safety, and Translational Positioning Across Cardiovascular Syndromes. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196392 | PubMed |
| 42181649 | Efficacy and safety of Shenqi Yangxin formula in patients with stable coronary artery disease based on CCTA: rationale, design, and study protocol for a randomized, double-blind, placebo-controlled study. | Front Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42181649 | PubMed |
| 42163171 | Joint effects of dyslipidemia and the platelet count on stroke risk: Longitudinal analysis via dynamic lipid stratification in the CHARLS cohort. | BMC Neurol | 2026 | https://conductscience.org/library/papers/42163171 | PubMed |
| 42051358 | Beyond the conventional risk factors in the management of atherosclerosis in women: a call to action for careful consideration of obesity and inflammation. | Eur Heart J Open | 2026 | https://conductscience.org/library/papers/42051358 | PubMed |
| 42045490 | Mechanisms and therapeutic potential of colchicine in atherosclerotic cardiovascular disease. | Nat Cardiovasc Res | 2026 | https://conductscience.org/library/papers/42045490 | PubMed |
| 42033599 | Cardiovascular Benefit and Gastrointestinal Risk of Colchicine in Secondary Prevention: Risk Associated with Dose and Treatment Duration. | Am J Cardiovasc Drugs | 2026 | https://conductscience.org/library/papers/42033599 | PubMed |
| 41997618 | Association between C reactive protein and risk of incident heart failure in cancer survivors. | Open Heart | 2026 | https://conductscience.org/library/papers/41997618 | PubMed |
| 41892853 | The Mental Health-Acute Coronary Syndrome Continuum: Bidirectional Pathophysiological Links and Clinical Implications. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/41892853 | PubMed |
| 41832514 | M1 macrophage-derived migrasomes exacerbate post-myocardial infarction injury via guanylate binding protein 5. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41832514 | PubMed |
| 41827096 | Intracoronary Imaging for the Management of Vulnerable Plaques. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827096 | PubMed |
| 41667721 | Inhibition of STING pathway attenuates experimental abdominal aortic aneurysm progression. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/41667721 | PubMed |
| 41593670 | Neutrophil methylmalonic acid promotes microthrombus formation and adverse cardiac remodeling post-myocardial infarction through activating IL-6 signaling pathway-mediated NETosis. | BMC Med | 2026 | https://conductscience.org/library/papers/41593670 | PubMed |
| 41568554 | Colchicine in Patients With Recent Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | J Am Heart Assoc | 2026 | https://conductscience.org/library/papers/41568554 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 | NCBI Gene |
| MPO | 4353 | PubTator's text mining | https://conductscience.org/library/genes/4353 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| COLCHICINE | CHEMBL107 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL107 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39166327
GET https://conductscience.org/api/papers/v1/39166327/cited_by?page=2